815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
NIKE reported fiscal 2026 third-quarter results for the period ended February 28, 2026. Revenue was flat at $11.3 billion on a reported basis and down 3 percent on a currency-neutral basis, while net income fell 35 percent to $0.5 billion and diluted earnings per share fell to $0.35 from $0.54. For shareholders, the quarter shows lower profit on flat sales, with gross margin also down.
Revenues were $11.3 billion, flat reported and down 3 percent currency-neutral; NIKE Direct fell 4 percent to $4.5 billion.
Net income was $0.5 billion, down 35 percent; diluted EPS was $0.35 versus $0.54 a year earlier.
Gross margin decreased 130 basis points to 40.2 percent, primarily due to higher tariffs in North America.
The company returned about $609 million to shareholders through dividends in the quarter, up 3 percent.
BriaCell Therapeutics filed interim financial statements for its subsidiary BriaPro Therapeutics for the three and six months ended January 31, 2026, showing larger losses than a year earlier and a shareholders' deficit of $1,618,141. The filing states there is a material uncertainty about BriaPro's ability to continue as a going concern, and that it depends entirely on BriaCell for funding until it raises additional financing.
Six-month net loss was $472,231, compared with $233,185 in the prior-year period; three-month net loss was $227,493, compared with $151,062.
Six-month research and development expenses were $433,307, compared with $130,023 a year earlier.
Amounts due to related parties were $1,606,112 at January 31, 2026, and cash and cash equivalents were $1.
On February 18, 2026, BriaPro agreed to acquire BriaCell's license to Soluble CD80; the transaction closed March 30, 2026, with 23,972,589 shares issued to BriaCell and a credit facility of up to $3,000,000.
MiNK Therapeutics reported fourth-quarter and full-year 2025 results on March 31, 2026, along with a filing that furnishes its press release. The company's net loss widened for the full year, and it ended 2025 with $13.4 million in cash, which it says provides a runway through 2026 together with $3.0 million raised since year end under its at-the-market sales program.
Full-year 2025 net loss was $12.5 million, or $2.93 per share, compared with $10.8 million, or $2.86 per share, in 2024.
Fourth-quarter 2025 net loss was $2.6 million, or $0.56 per share, compared with $2.5 million, or $0.62 per share, in the fourth quarter of 2024.
Cash balance was $13.4 million at year end 2025; the company raised an additional $3.0 million through its at-the-market program after year end.
The press release cites a C-Further Consortium collaboration providing up to $1.1 million in non-dilutive funding; the filing reports no revenue figures.
DiaMedica Therapeutics reported full-year 2025 results showing a wider net loss of $32.8 million, or $0.70 per share, compared with $24.4 million, or $0.60 per share, in 2024, as research and development and general and administrative costs rose. The company ended 2025 with $59.9 million in cash and short-term investments, which it says will fund operations through the second half of 2027, after share sales in July 2025 and under its at-the-market program.
Net loss for 2025 was $32.8 million, or $0.70 per share, versus $24.4 million, or $0.60 per share, in 2024.
Research and development expenses rose to $24.6 million from $19.1 million, driven mainly by the ReMEDy2 trial and its global expansion.
General and administrative expenses rose to $9.8 million from $7.6 million, including higher share-based compensation.
Cash and short-term investments were $59.9 million at December 31, 2025, up from $44.1 million a year earlier.
Interlink Electronics reported fourth-quarter 2025 revenue of $2.85 million, down from $2.99 million a year earlier, as lower force-sensing shipments outweighed gains in gas-sensor and Calman Technology printed electronics sales. Gross margin fell to 31.7% from 39.6%, and the net loss widened to $574,000 from $413,000, so headline revenue and profit both moved lower for shareholders. The same filing discloses discretionary bonuses for the CEO and CFO for fiscal 2025.
Q4 2025 revenue was $2.85 million versus $2.99 million, down 4.5%, driven by lower force-sensing product shipments.
Q4 gross margin was 31.7% versus 39.6%; net loss was $574,000 versus $413,000.
Full-year 2025 revenue was $11.89 million, up 1.8%, while full-year net loss narrowed to $1.62 million from $1.98 million.
On March 25, 2026, the compensation committee approved bonuses of $60,000 for CEO Steven N. Bronson and $20,000 for CFO Ryan J. Hoffman for fiscal 2025.
VirTra reported fourth-quarter and full-year 2025 results, with full-year revenue down 15% to $22.4 million and net income falling to $0.3 million, or $0.02 per diluted share, from $1.4 million, or $0.12, a year earlier. Management attributed the decline to delayed federal funding that affected awards, purchasing and deliveries, and said Q4 bookings improved to $7.3 million and backlog was $25.6 million.
Full-year revenue was $22.4 million versus $26.4 million (restated) in 2024; gross margin was 68% versus 74%.
Q4 2025 revenue was $2.9 million versus $4.7 million a year earlier; Q4 net loss was $1.0 million, or $0.09 per diluted share.
Adjusted EBITDA, a non-GAAP measure, was $1.6 million for 2025 versus $2.9 million in 2024.
Bookings were $7.3 million in Q4 and $26.7 million for 2025; backlog was $25.6 million at December 31, 2025.
Sypris reported fourth-quarter 2025 revenue of $30.3 million, down from $33.4 million a year earlier, and a net loss of $3.9 million ($0.17 per share) compared with net income of $0.1 million. For full-year 2025, revenue was $119.9 million versus $140.2 million and the net loss was $6.3 million, which matters to shareholders because both headline revenue and profit measures weakened. Management cited tariffs and regulatory uncertainty affecting Sypris Technologies, while Sypris Electronics revenue rose.
Q4 2025 revenue of $30.3 million vs. $33.4 million; net loss of $3.9 million, or $0.17 per share, vs. net income of $0.1 million, or $0.01 per diluted share
Full-year 2025 revenue of $119.9 million vs. $140.2 million; net loss of $6.3 million, or $0.28 per share, vs. a net loss of $1.7 million, or $0.08 per share
Sypris Technologies Q4 revenue fell to $12.5 million from $19.5 million; Sypris Electronics Q4 revenue rose 27.6% to $17.7 million
Sypris Electronics Q4 gross profit included $1.0 million of inventory charges; 2026 annual meeting set for June 16, 2026 in Louisville, Kentucky
KB Home reported first-quarter results for the three months ended February 28, 2026, with revenues down 23% to $1.08 billion and net income down to $33.4 million from $109.6 million. Diluted earnings per share fell to $0.52 from $1.49, and the company said it repurchased $50.0 million of common stock, which supported per-share results.
Homes delivered fell 14% to 2,370, and average selling price was $452,100 compared with $500,700.
Homebuilding operating income was $33.0 million versus $127.3 million; housing gross profit margin was 15.3% versus 20.2%.
Net orders rose 3% to 2,846, while ending backlog was 3,604 homes worth $1.70 billion, compared with 4,436 homes worth $2.20 billion a year earlier.
For the second quarter, guidance calls for 2,250 to 2,450 deliveries and housing revenues of $1.05 billion to $1.15 billion.
Marker Therapeutics reported results for the year ended December 31, 2025, with grant income of $3.5 million, down from $6.6 million in 2024, and a net loss of $12.2 million, up from $10.7 million. The company said its existing cash and cash equivalents will fund operating expenses through the fourth quarter of 2026, assuming no additional grant funds are received.
Grant income was $3.5 million for 2025, versus $6.6 million for 2024.
Net loss was $12.2 million, or $0.79 per share, versus $10.7 million, or $1.19 per share, in 2024.
Research and development expenses were $11.8 million, versus $13.5 million in 2024; general and administrative expenses were $4.2 million, flat year over year.
Cash, cash equivalents and restricted cash were $17 million at December 31, 2025, which the company expects to fund operations through the fourth quarter of 2026.
General Mills reported fiscal 2026 third-quarter results on March 18, 2026, with net sales of $4.4 billion, down 8%, and diluted EPS of $0.56, down 50%. The company reaffirmed its full-year fiscal 2026 targets, which include adjusted operating profit and adjusted diluted EPS both expected to be down 16 to 20 percent in constant currency. For shareholders, the quarter shows steep declines in sales and earnings, while the unchanged outlook signals that management still expects a fourth-quarter improvement.
Third-quarter net sales were $4.4 billion, down 8%, with organic net sales down 3%.
Diluted EPS was $0.56, down 50%; adjusted diluted EPS was $0.64, down 37% in constant currency.
Operating profit was $525 million, down 41%; nine-month operating profit rose 6% to $3.0 billion, driven by a $1.0 billion gain on divestitures.
Full-year fiscal 2026 organic net sales are expected to be down 1.5 to 2 percent.
Townsquare Media reported fourth-quarter 2025 net revenue of $106.5 million, down 9.6% from a year earlier, and a net loss of $4.8 million compared with net income of $25.0 million in the prior-year quarter. Adjusted EBITDA fell 30.9% to $21.5 million, and the company said results met its previously issued guidance; it also kept its quarterly dividend at $0.20 per share and issued 2026 guidance of $420 million to $440 million in full-year net revenue.
Q4 2025 net revenue fell to $106.5 million from $117.8 million; Adjusted EBITDA fell to $21.5 million from $31.2 million
Full-year 2025 net loss narrowed to $9.8 million from $10.9 million; full-year net revenue fell 5.2% to $427.4 million
2026 guidance: first-quarter net revenue of $96 million to $98 million and full-year net revenue of $420 million to $440 million
Quarterly dividend of $0.20 per share maintained, payable May 4, 2026 to holders of record as of April 27, 2026
Lennar reported first-quarter 2026 results for the period ended February 28, 2026, with net earnings attributable to Lennar of $229 million, or $0.93 per diluted share, down from $520 million, or $1.96 per diluted share, a year earlier. Total revenues were $6.6 billion, compared with $7.6 billion, as home deliveries fell 5% and the average sales price dropped to $374,000 from $408,000. The company also gave second-quarter 2026 delivery and margin guidance.
Net earnings $229 million, or $0.93 per diluted share, versus $520 million, or $1.96, in Q1 2025
Total revenues $6.6 billion versus $7.6 billion; gross margin on home sales 15.2% versus 18.7%
Q2 2026 guidance: 20,000 to 21,000 deliveries and gross margin of 15.5% to 16.0%
Repurchased 2 million shares for $237 million during the quarter
Income Opportunity Realty Investors reported results for the quarter ended December 31, 2025, with net income of $1.0 million, or $0.25 per diluted share, down from $1.1 million, or $0.27 per share, a year earlier. The company said the decline reflects lower interest income, partly offset by higher advisory fees, and full-year 2025 net income also fell to $4.0 million ($0.98 per share) from $4.7 million ($1.14 per share).
Q4 2025 net income: $1.0 million, or $0.25 per diluted share, versus $1.1 million, or $0.27 per share, in Q4 2024
Q4 2025 interest income from related parties: $1.3 million, versus $1.5 million in Q4 2024
Full-year 2025 net income: $4.0 million ($0.98 per share), versus $4.7 million ($1.14 per share) in 2024
Cracker Barrel reported fiscal 2026 second-quarter revenue of $874.8 million, down 7.9% from the prior year quarter, with GAAP diluted EPS of $0.06 versus $0.99 a year earlier. The company narrowed its fiscal 2026 outlook, with adjusted EBITDA now expected at $85 million to $100 million, compared with the previous $70 million to $110 million range.
Q2 total revenue $874.8 million, down 7.9%; comparable store restaurant sales down 7.1% and comparable store retail sales down 9.2%
GAAP diluted EPS $0.06 vs. $0.99; adjusted diluted EPS $0.25 vs. $1.38; GAAP net income $1.3 million vs. $22.2 million
Fiscal 2026 outlook: revenue $3.24 billion to $3.27 billion (previously $3.2 billion to $3.3 billion); adjusted EBITDA $85 million to $100 million (previously $70 million to $110 million)
Expects a net cash benefit of about $46 million in the third quarter from settlement of certain litigation; quarterly dividend of $0.25 per share payable May 13, 2026
Bath & Body Works reported fourth-quarter 2025 net sales of $2,724 million, down 2%, and diluted EPS of $1.99 versus $2.09 a year earlier. It guided fiscal 2026 net sales down 4.5% to 2.5% and adjusted diluted EPS of $2.40 to $2.65, compared with adjusted EPS of $3.21 in 2025, which signals lower profit for shareholders.
Q4 2025 net sales were $2,724 million, down from $2,788 million; operating income was $599 million versus $678 million.
Q4 2025 diluted EPS was $1.99 ($2.05 adjusted), compared with $2.09 a year earlier.
Full-year 2026 guidance: net sales down 4.5% to 2.5%; adjusted diluted EPS of $2.40 to $2.65, compared with $3.21 in 2025.
Company expects free cash flow of approximately $600 million in fiscal 2026 and assumes no share repurchases.
Versant Media Group reported full-year 2025 results showing declines in revenue, net income and Adjusted EBITDA compared with 2024. The company also declared a $0.375 per share quarterly dividend and authorized its first share repurchase program of up to $1 billion, which matters to shareholders as a new capital return commitment alongside weaker results.
2025 revenue was $6.69 billion, down 5.3% from $7.06 billion in 2024
Net income attributable to Versant was $930 million, down 31.8% from $1.36 billion
Adjusted EBITDA was $2.42 billion, down 14.5%; Standalone Adjusted EBITDA was $2.18 billion, down 9.1%
Quarterly dividend of $0.375 per share is payable April 22, 2026 to holders of record on April 1, 2026
Berkshire Hathaway reported fourth-quarter 2025 net earnings attributable to shareholders of $19.2 billion, down from $19.7 billion a year earlier, and full-year net earnings of $67.0 billion, down from $89.0 billion in 2024. Operating earnings also declined, to $10.2 billion in the quarter from $14.5 billion and to $44.5 billion for the year from $47.4 billion. The company said quarterly investment gains and losses, which include unrealized market changes, can make per-share figures misleading.
Q4 2025 net earnings were $19.2 billion versus $19.7 billion in Q4 2024; Q4 operating earnings were $10.2 billion versus $14.5 billion.
Full-year 2025 net earnings were $67.0 billion versus $89.0 billion in 2024; full-year operating earnings were $44.5 billion versus $47.4 billion.
Net earnings per Class B share were $8.90 in Q4 2025 versus $9.13 in Q4 2024, and $31.04 for the full year versus $41.27.
Other-than-temporary impairments on Kraft Heinz and Occidental reduced 2025 earnings by $4.5 billion in Q4 and $8.3 billion for the full year; insurance float was about $176 billion at December 31, 2025.
Alamo Group reported fourth quarter 2025 net sales of $373.7 million, down 3.0% from a year earlier, and fully diluted EPS of $1.28 versus $2.33. For the full year, net sales fell 1.5% to $1,603.7 million and diluted EPS fell to $8.59 from $9.63, while the company raised its quarterly dividend 13.3% to $0.34 per share.
Q4 2025 adjusted fully diluted EPS was $1.70, compared with $2.39 in Q4 2024.
Vegetation Management Division Q4 net sales fell 13.2% to $138.7 million, and its adjusted EBITDA margin was 2.3%.
Industrial Equipment Division Q4 net sales rose 4.2% to $234.9 million, with adjusted EBITDA of $41.5 million.
The quarterly dividend increased from $0.30 to $0.34 per share, and the Petersen Industries acquisition closed in January 2026.
Biglari Holdings reported a fourth-quarter 2025 net loss attributable to shareholders of $49.9 million, compared with a $10.3 million loss a year earlier, and a full-year 2025 net loss of $37.5 million, compared with $3.8 million in 2024. The company said pre-tax operating earnings swung to a loss in the quarter, and investment losses drove most of the decline, which matters to shareholders because the reported results are weighed down by investment marks rather than operations alone.
Fourth-quarter 2025 pre-tax operating loss of $1.7 million, versus pre-tax operating earnings of $3.9 million in Q4 2024
Fourth-quarter investment losses of $62.3 million, versus $21.9 million a year earlier
Full-year 2025 pre-tax operating earnings of $18.8 million, down from $32.6 million in 2024
Book value per Class A equivalent share was $2,059.32 at December 31, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.